hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06363539, orgStudyIdInfo id: Adeel5, briefTitle: Silver Nitrate Versus Topical Steroid For Umbilical Granuloma, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-20, primaryCompletionDateStruct date: 2023-03-20, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Children Hospital and Institute of Child Health, Lahore, class: OTHER, descriptionModule briefSummary: Umbilical granuloma is most frequent abnormality of umbilicus in infants that is defined as a moist, fleshy and pink granulation tissue at the center of umbilicus. The most commonly used treatment for umbilical granuloma is silver nitrate cauterization. Various other treatment options for umbilical granuloma include dressing with alcohol and antiseptic solutions, topical table salt, topical steroid application, suture ligation, surgical excision, electrocautery and cryotherapy. Topical steroid ointment is easily available in market, it is cheaper and safer than silver nitrate. OBJECTIVE: To compare the outcome of treatment with silver nitrate versus topical steroid for umbilical granuloma in terms of healing after 3 weeks of treatment. MATERIALS AND METHODS Study Design: Randomized Controlled Trial Setting: Department of Pediatric Surgery, Children Hospital, Lahore Duration: 6 months after approval of synopsis \[Sept 20, 2022 till March 20, 2023\] DATA COLLECTION PROCEDURE 2 After approval of study from hospital Ethical committee \& CPSP, all patients fulfilling the inclusion criteria were admitted through the pediatric surgery outpatient department of The Children's Hospital Lahore. 354 Patients were divided in two equal groups randomly, using lottery method Group A (control group) in which silver nitrate was applied to the lesion once a week and Group B (experimental group) in which topical steroid ointment was applied to the lesion twice a day. Patients were followed after 3 weeks to see healing of umbilical granuloma. Photographs were taken before start of treatment and on regular intervals at each follow up visit. All data was collected by myself., conditionsModule conditions: Umbilical Granuloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized control trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 354, type: ACTUAL, armsInterventionsModule interventions name: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION, interventions name: Silver Nitrate, outcomesModule primaryOutcomes measure: healing, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 1 Year, stdAges: CHILD, contactsLocationsModule locations facility: Children Hospital, city: Lahore, state: Punjab, zip: 42000, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06363526, orgStudyIdInfo id: UMalagaDRIP, briefTitle: Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy., acronym: DMDrespy2024, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-05, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of Malaga, class: OTHER, descriptionModule briefSummary: The purpose of this study is to analyze the effectiveness of a 5-weeks respiratory digital intervention program in patients with Duchenne muscular dystrophy and Becker muscular dystrophy., conditionsModule conditions: Duchenne Muscular Dystrophy, conditions: Becker Muscular Dystrophy, conditions: Muscular Dystrophy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 12 participants were randomized to follow a digital respiratory physiotherapy program for 5 weeks. The participants were evaluated at the beginning and at the end of the study, and the results will be measured before and after each intervention during the study., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Digital respiratory intervention program, outcomesModule primaryOutcomes measure: Analyze the improvement of the forced vital capacity (FVC)., secondaryOutcomes measure: Perform an anthropometric study of the patient's characteristics, taking into account weight; and also a general physical examination., secondaryOutcomes measure: Perform an anthropometric study of the patient's characteristics, taking into account age., secondaryOutcomes measure: Perform an anthropometric study of the patient's characteristics, taking into account height., secondaryOutcomes measure: Perform an anthropometric study of the patient's characteristics, taking into account sex., secondaryOutcomes measure: Examine changes in forced expiratory pressure, secondaryOutcomes measure: Analyze changes in maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)., secondaryOutcomes measure: Check if there are changes in the sniff nasal inspiratory pressure (SNIP), secondaryOutcomes measure: Evaluate the fatigue in patients using an EPInfant test., secondaryOutcomes measure: Evaluate the quality of life of patients using a scale called "Kindscreen-52"., eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 20 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Rocío Martín-Valero, city: Málaga, country: Spain, geoPoint lat: 36.72016, lon: -4.42034, hasResults: False
protocolSection identificationModule nctId: NCT06363487, orgStudyIdInfo id: R87970/RE001, briefTitle: Semaglutide and Cognition in Healthy Volunteers, acronym: OxSENSE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-04-08, completionDateStruct date: 2024-06-08, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of Oxford, class: OTHER, collaborators name: NIHR Oxford Health Biomedical Research Centre, descriptionModule briefSummary: Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA). It is a safe medication approved for use in type-2 diabetes mellitus (T2DM) and obesity. Primarily, it works by counteracting insulin-resistance and inducing weight loss. It also acts on several other interconnected neurobiological, immunological (esp. inflammatory), endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms. Its effects on cognition and energy are currently unknown. In this study we are using semaglutide as an experimental tool to further investigate these relationships., conditionsModule conditions: Cognitive Change, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide, 0.5 mg/mL, interventions name: Placebo, 0.9% NaCl 1.5mL, outcomesModule primaryOutcomes measure: Reward (learning), primaryOutcomes measure: Reward (effort-based), primaryOutcomes measure: Reward (primary), secondaryOutcomes measure: Emotional processing, secondaryOutcomes measure: Emotional impulsivity, secondaryOutcomes measure: Memory (short- and medium-term) processing, secondaryOutcomes measure: Memory (working) processing, secondaryOutcomes measure: Energy/activity, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Psychiatry, University of Oxford, city: Oxford, state: Oxfordshire, zip: OX3 7JX, country: United Kingdom, geoPoint lat: 51.75222, lon: -1.25596, hasResults: False
protocolSection identificationModule nctId: NCT06363448, orgStudyIdInfo id: Soh-Med-24-3-04PD, briefTitle: Yamani Technique Versus Proline Mesh for Intraocular Lens Scleral Fixation in Aphakia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The study aims to describe a new method of sulcus fixation of intraocular lenses (IOLs) using a prolene mesh and to compare its outcomes with Yamani technique., conditionsModule conditions: Aphakia, Postcataract, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia, outcomesModule primaryOutcomes measure: Best corrected visual acuity (BCVA) in LogMAR, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ophthalmology department, Sohag University, status: RECRUITING, city: Sohag, zip: 82511, country: Egypt, contacts name: Elshimaa A.Mateen, role: CONTACT, phone: 0201282223427, email: elshimaa.moussa@yahoo.com, geoPoint lat: 26.55695, lon: 31.69478, locations facility: Elshimaa A.Mateen, status: RECRUITING, city: Sohag, country: Egypt, contacts name: Elshimaa A.Mateen, Doctor, role: CONTACT, phone: 0201282223427, email: elshimaa.moussa@yahoo.com, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06363435, orgStudyIdInfo id: #2022-01302-02-PSMA, briefTitle: AI-based Measurements of Tumour Burden in PSMA PET-CT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2031-03, completionDateStruct date: 2033-03, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Elin Tragardh, class: OTHER, collaborators name: Lund University, descriptionModule briefSummary: The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence)., conditionsModule conditions: Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1500, type: ESTIMATED, armsInterventionsModule interventions name: AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans, outcomesModule primaryOutcomes measure: Tumour burden (cm3) in relation to overall survival, secondaryOutcomes measure: Tumour burden (cm3) in relation to biochemical recurrence, secondaryOutcomes measure: Number of tumours/metastases in relation to OS, secondaryOutcomes measure: Comparing two different segmentation methods in relation to OS, secondaryOutcomes measure: Comparing total tumour burden (cm3) measured manually and by the AI-based mehtod, eligibilityModule sex: MALE, minimumAge: 20 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Skåne University Hospital, status: RECRUITING, city: Lund, country: Sweden, contacts name: Elin Tragardh, Prof, role: CONTACT, phone: +4640338724, email: elin.tragardh@skane.se, geoPoint lat: 55.70584, lon: 13.19321, locations facility: Skåne university hospital, status: RECRUITING, city: Malmö, country: Sweden, contacts name: Elin Tragardh, Prof, role: CONTACT, phone: +4640338724, email: elin.tragardh@skane.se, geoPoint lat: 55.60587, lon: 13.00073, hasResults: False
protocolSection identificationModule nctId: NCT06363422, orgStudyIdInfo id: JY2024-012, briefTitle: The Value of Epicanthoplasty on the Modification of Upper-eyelid Appearance, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-03-15, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, class: OTHER, descriptionModule briefSummary: In East Asian populations, the combination of an epicanthic fold and mono-eyelid is one of their anatomical characteristics. Misalignment of the orbicularis oculi muscle and fibrous connections leads to longitudinal tension, forming the epicanthic fold. The epicanthic fold may diminish the aesthetic effects of eyelid cosmetic surgery, shorten the horizontal length, and affect the postoperative shape of double eyelids. As upper eyelid cosmetic surgery is one of the most common cosmetic procedures in Asia, there is increasing attention on the modification of the epicanthic fold and its impact on the formation of double eyelids., conditionsModule conditions: Patient Satisfaction, conditions: Epicanthus; Fold, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: Epicanthoplasty, outcomesModule primaryOutcomes measure: inter-epicanthal distance (IED), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai ninth people's hospital, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06363409, orgStudyIdInfo id: 2023-1353, briefTitle: The Acute and Accumulative Effects of Snack Foods on Exercise Recovery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: San Diego State University, class: OTHER, descriptionModule briefSummary: The purpose of the research is two-fold. One goal is to determine if post-exercise almond or cereal bar consumption can promote muscle gain as well as increasing muscular strength throughout an eight-week weight training program. The other goal is to assess the short-term effects of almonds or cereal bar on recovery that may explain the overall long-term adaptations., conditionsModule conditions: Muscle Strength, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Cereal Bar as a recovery food snack, interventions name: Almond, outcomesModule primaryOutcomes measure: delayed onset of muscle soreness, primaryOutcomes measure: markers of muscle damage, primaryOutcomes measure: changes in strength, primaryOutcomes measure: changes in body composition, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06363396, orgStudyIdInfo id: K 2023-7081, briefTitle: Fatigue and Cognitive Dysfunction After Allogeneic Stemcell Transplantation, Prospective PET Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2026-02-22, completionDateStruct date: 2027-02-22, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: Karolinska University Hospital, descriptionModule briefSummary: This study is the academic study and continuation and further development of a prior project under the leadership of Professor LeBlanc. Patients undergoing allogenic stem cell transplantation are followed up in the outpatient clinic. Here, patients are offered participation the fatigue study measuring both fatigue and cognitive impairment systematically by international standard. Previous study by Boberg et al suggested distinct mRNA and proteomic profiles segregating fatigued from non-fatigued patients as well as patients with or without cognitive impairment. A larger well-defined patient cohort is necessary to confirm these results. Investigators aim to identify specific sets of proteins in the CSF that can serve as potential biomarkers of cognitive dysfunction and/or fatigue. This will be performed with two methods:* by using mass spectrometry-based proteomics approaches* Olink technologyPET examinations will be performed on both fatigued and non-fatigued. We will utilize the second generation TSPO radioligand \[ 11C\]PBR28 as well as the SV2A radioligand \[ 11C\]UCB-J, both showing high signal-to-noise ratio and adequate test-retest properties., conditionsModule conditions: Fatigue, conditions: Cognitive Dysfunction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Results of cognitive tests, primaryOutcomes measure: Potential biomarkers for fatigue and cognitive dysfunction, primaryOutcomes measure: PET results, secondaryOutcomes measure: Global analyses of the neural connections, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Karolinska, status: RECRUITING, city: Stockholm, zip: 14186, country: Sweden, contacts name: Ksenia Boriskina, MD, role: CONTACT, phone: 0858580675, email: ksenia.boriskina@regionstockholm.se, contacts name: Kirsti Niemelä, study nurse, role: CONTACT, contacts name: Katarina Le Blanc, professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06363383, orgStudyIdInfo id: MB-001-101, briefTitle: A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-09, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Mage Biologics, class: INDUSTRY, collaborators name: Alimentiv Inc., descriptionModule briefSummary: The goal of this clinical trial is to learn if the oral biologic MB-001 is safe in healthy volunteers. The main questions it aims to answer are:Is the drug safe when administered orally at increasing doses? Researchers will compare the drug with placebo to see if there are more side effects in those receiving the drug.Participants will receive a single or five daily doses of the drug or placebo and will be asked to stay in the clinic for five days following the last dose., conditionsModule conditions: Ulcerative Colitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: two-stage, single-center, double-blinded, randomized, placebo-controlled, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: double-blinded using matching placebo capsules containing matching pellets, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: MB-001, outcomesModule primaryOutcomes measure: Incidence and severity of adverse events (AEs), primaryOutcomes measure: Clinically significant changes from baseline in vital signs, primaryOutcomes measure: Clinically significant changes from baseline in physical examination findings, primaryOutcomes measure: Clinically significant changes from baseline in clinical laboratory assessments, primaryOutcomes measure: Clinically significant changes from baseline in ECG parameters, secondaryOutcomes measure: Area under the concentration-time curve, secondaryOutcomes measure: Maximum plasma concentration, secondaryOutcomes measure: Time to reach observed maximum plasma concentration after administration, secondaryOutcomes measure: Trough concentration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CMAX, status: RECRUITING, city: Adelaide, state: South Australia, zip: 5000, country: Australia, contacts name: Jessica Lehman, role: CONTACT, phone: +61 8 7088 7900, email: cmax@cmax.com.au, geoPoint lat: -34.92866, lon: 138.59863, hasResults: False
protocolSection identificationModule nctId: NCT06363370, orgStudyIdInfo id: KXZY-GB05-201, briefTitle: Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Kexing Biopharm Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection., conditionsModule conditions: Respiratory Syncytial Virus Infections, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 322, type: ESTIMATED, armsInterventionsModule interventions name: Human interferon α1b Inhalation Solution, interventions name: Inhalation Solution Placebo, outcomesModule primaryOutcomes measure: Wang bronchiolitis score chanced by percentage from baseline, primaryOutcomes measure: Wang bronchiolitis score chanced by percentage from baseline, primaryOutcomes measure: Wang bronchiolitis score of 0 in proportion, primaryOutcomes measure: Wang bronchiolitis score total score < 5 points, primaryOutcomes measure: Wang bronchiolitis score, the first time the total score reaches < 5 points, secondaryOutcomes measure: RSV viral load, eligibilityModule sex: ALL, minimumAge: 2 Months, maximumAge: 2 Years, stdAges: CHILD, contactsLocationsModule locations facility: Children's Hospital, Capital Institute of Pediatrics, status: RECRUITING, city: Beijing, state: Beijing, zip: 100000, country: China, contacts name: Ling Cao, MD, role: CONTACT, phone: 13910610319, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False